ELI LILLY AND COMPANY |
Market Closed -
Other stock markets
|
Pre-market 08:18:44 am | |||
| 865 USD | +1.77% |
|
884.2 | +2.22% |
| 01:07pm | Stocks Fall Pre-Bell Ahead of Fed Policy Meeting; Asia Churns, Europe Down | MT |
| 12:29pm | Futures fall as markets await Fed decision, CPI data | RE |
Financials (USD)
| Sales 2024 * | 42.98B | Sales 2025 * | 52.62B | Capitalization | 779B |
|---|---|---|---|---|---|
| Net income 2024 * | 11.93B | Net income 2025 * | 16.55B | EV / Sales 2024 * | 18.5 x |
| Net Debt 2024 * | 18.07B | Net Debt 2025 * | 15B | EV / Sales 2025 * | 15.1 x |
| P/E ratio 2024 * |
64.7
x | P/E ratio 2025 * |
46.6
x | Employees | 43,000 |
| Yield 2024 * |
0.6% | Yield 2025 * |
0.69% | Free-Float | 99.8% |
More Fundamentals
* Assessed data
More news
Latest transcript on Eli Lilly and Company
More recommendations
More press releases
More news
| 1 day | +2.25% | ||
| 1 week | +4.06% | ||
| Current month | +5.44% | ||
| 1 month | +13.82% | ||
| 3 months | +13.50% | ||
| 6 months | +44.64% | ||
| Current year | +48.39% |
1 week
817.62
871.63
1 month
750.53871.63
Current year
579.05871.63
1 year
434.34871.63
3 years
217.00871.63
5 years
101.36871.63
10 years
58.50871.63
| Managers | Title | Age | Since |
|---|---|---|---|
David Ricks
CEO | Chief Executive Officer | 56 | 95-12-31 |
Ruth Gimeno
PSD | President | - | - |
David Hyman
CTO | Chief Tech/Sci/R&D Officer | - | 23-10-15 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 63 | 21-01-24 | |
Ralph Alvarez
BRD | Director/Board Member | 68 | 09-03-31 |
Jon Fyrwald
BRD | Director/Board Member | 63 | 04-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 6.49% | 21 M€ | +8.03% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-10 | 865 | +1.77% | 3,444,498 |
| 24-06-07 | 850 | +1.52% | 2,468,834 |
| 24-06-06 | 837.3 | +0.66% | 2,108,975 |
| 24-06-05 | 831.8 | -0.10% | 2,169,003 |
| 24-06-04 | 832.6 | +0.16% | 1,748,288 |
Delayed Quote Nyse, June 10, 2024 at 04:01 pm EDT
More quotes
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
865
USD
Average target price
855.2
USD
Spread / Average Target
-1.14%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +48.39% | 779B | |
| -6.13% | 354B | |
| +20.61% | 333B | |
| +10.00% | 301B | |
| +17.13% | 249B | |
| -1.88% | 216B | |
| +11.05% | 214B | |
| +5.80% | 163B | |
| -2.50% | 159B | |
| +0.19% | 121B |
- Stock Market
- Equities
- LLY Stock
